Oculis Holding AG (OCS) EBITDA (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly EBITDA of $463552.7 in Q1 2026, down 34.89% quarter-over-quarter from $711915.6 in Q4 2025, and up 2.15% on a YoY basis from $453798.2 in Q1 2025.
Oculis Holding AG (OCS) EBITDA (2022 - 2026) Analysis & Trends
Oculis Holding AG's EBITDA history runs 5 years deep, the most recent figure standing at $463552.7 for Q1 2026.
- In Q1 2026, EBITDA rose 2.15% year-over-year to $463552.7; the TTM figure through Mar 2026 stood at $1.8 million (down 99.95% YoY), while the FY2025 annual figure was $2.2 million, up 75.15% from the prior year.
- EBITDA was $463552.7 for Q1 2026 at Oculis Holding AG, down from $711915.6 in the prior quarter.
- In the past five years, EBITDA ranged from a high of $3.4 billion in Q4 2024 to a low of $141062.6 in Q3 2024.
- Historically, EBITDA has averaged $214.4 million across 5 years, with a median of $311286.7 in 2023.
- The sharpest annual moves came in 2024 and 2025: EBITDA jumped 1172805.13% in 2024, then plunged 99.98% in 2025.
- A 5-year view of EBITDA shows it stood at $222136.7 in 2022, then surged by 31.44% to $291984.8 in 2023, then surged by 1172805.13% to $3.4 billion in 2024, then slumped by 99.98% to $711915.6 in 2025, then plunged by 34.89% to $463552.7 in 2026.
- The last three EBITDA figures came in at $463552.7 (Q1 2026), $711915.6 (Q4 2025), and $190320.4 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 463,552.70 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 463,552.70 |
| Dec 31, 2025 | 711,915.61 |
| Sep 30, 2025 | 190,320.42 |
| Jun 30, 2025 | 451,750.95 |
| Mar 31, 2025 | 453,798.22 |
| Dec 31, 2024 | 3.42 Bn |
| Sep 30, 2024 | 141,062.59 |
| Jun 30, 2024 | 369,335.02 |
| Mar 31, 2024 | 337,976.28 |
| Dec 31, 2023 | 291,984.81 |
| Sep 30, 2023 | 330,588.55 |
| Jun 30, 2023 | 278,043.89 |
| Mar 31, 2023 | 247,586.23 |
| Dec 31, 2022 | 222,136.69 |
| Sep 30, 2022 | 209,162.24 |
| Jun 30, 2022 | 249,190.32 |